Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 3, 2007, Pages 217-221

  Chatley, P ^a   Badyal, Dinesh K ^a   Calton, R ^a   Khosla, P P ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Atorvastatin; Combination; Fenofibrate; Hyperlipidemia

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ACIDITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ALANINE TRANSAMINASE; ANTILIPEMIC AGENTS; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL; CREATINE KINASE; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROCETOFEN; PYRROLES; TRIGLYCERIDES;

EID: 34250351903     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.3.1075363     Document Type: Article

References (14)

1. Mahley, R.W., Bersot, T.P. Drug therapy for hypercholesterolemia and dyslipidemia. In: The Pharmacological Basis of Therapeutics, 10th ed. Hardman, J.G., Limbrid, L.E. (Eds.). McGraw-Hill: New York 2001, 971-1002.
2. Ballantyne, C.M. Low density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998, 82: 3-12.
3. Grundy, S.M. Approach to lipoprotein management in 2001 national cholesterol guidelines. Am J Cardiol 2002, 90(Suppl C): 111-211.
4. Castelli, W.P., Garrison, R.J., Wilson, P.W., Abott, R.D., Kalousdian, S., Karmel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. J Am Med Assoc 1986, 256: 2835-8.
5. Thompson, G.R. What targets should lipid-modulating therapy achieve to optimize the prevention of coronary heart disease? Atherosclerosis 1997, 131: 1-5.
6. Brown, G., Albers, J.J., Fisher, Z.D. et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein-B. N Engl J Med 1990, 323: 1289-98.
7. Bakker-Arkema, R.G., Davidson, M.H., Goldstein, R.J. et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin in patients with hypertriglyceridemia. J Am Med Assoc 1996, 275: 128-33.
8. Grover, S.A., Palmer, C.S., Caupal, L. Serum lipid screening to identify high risk individuals for coronary death: The results of the lipid research clinics prevalence cohort. Arch Intern Med 1994, 154: 679-84.
9. Pasternak, R.C., Smith, S.C., Jr., Bairey-Merz, C.N., Grundy, S.M., Cleeman, J.I., Lenfant, C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40: 568-73.
10. Xydakis, A.M., Ballantyne, C.M. Combination therapy for combined dyslipidemia. Am J Cardiol 2002, 90(Suppl): 21K-29K.
11. Stepherd, J. The statin era: In search of the ideal lipid regulating agent. Heart 2001, 85: 259-64.
12. Jones, P., Kafonek, S., Laurora, I., Hurminghake, D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 1995, 8: 582-7.
13. Davidson, M.H. Combination therapy for dyslipidemia: Safety and regulatory considerations. Am J Cardiol 2002, 90(Suppl): 50K-60K.
14. McKenney, J. Combination therapy for elevated low density lipoprotein cholesterol: The key to coronary artery disease risk reduction. Am J Cardiol 2002, 90(Suppl): 8K-20K.